A New Momentum for Renal Denervation: 2023 ESH Guidelines

Published: 12 December 2023

  • Views:

    Views Icon 5168
  • Likes:

    Heart Icon 7
  • episode_image
    20m 15s
    Part 5 Q&A
    Joost Daemen, Dagmara Hering
Average (ratings)
No ratings
Your rating

Overview

In light of the recent ESC clinical consensus statement on Renal Denervation (RDN), a significant development has occurred in the management of hypertension. The European Society of Hypertension (ESH) has officially endorsed Renal Denervation as a recommended treatment for hypertension. This marks a pivotal moment in the field of hypertension management.

 

This broadcast features a compelling discussion between two distinguished experts, Dr Joost Daemen (Erasmus University Medical Center, Rotterdam, NL) and Prof Dagmara Hering (Medical University of Gdańsk, Gdańsk, PL). They provide invaluable insights into how these new guidelines impact their approach to patient selection and the adjustments that should be made in the patient care pathway for hypertension treatment. Gain a deeper understanding of the evolving landscape of hypertension management in this engaging conversation.

This programme is supported by

Learning Objectives

  • Learn about the 2023 ESH guidelines about Renal Denervation
  • Deep dive into class of recommendation and level of evidence
  • Overview of Ultrasound RDN clinical evidence
  • Understand recommended patient pathways and hear case discussions.

Target Audience

  • Interventional Cardiologist
  • Hypertension Specialist
  • General Physician
  • Nephrologist
  • Cardiologist
  • Internal medicine

More from this programme

Part 1

ESH 2023 Guidelines – What’s new?

Part 2

Ultrasound RDN Clinical Evidence

Part 3

Who to Treat With RDN?

Part 4

How to Build the Therapy?

Part 5

Q&A

1 session
Q&A Watch now

Faculty Biographies

Joost Daemen

Joost Daemen

Interventional Cardiologist

Dr Joost Daemen, MD, PhD is a senior interventional cardiologist at the Thorax Center, Erasmus MC, Rotterdam, NL. Dr Daemen obtained his degree in medicine at the Erasmus University Medical Center, Rotterdam in 2005 and did 2 years of internal medicine training and 4 years of general cardiology training at the Thoraxcenter, Rotterdam. 

Dr Daemen is actively involved in several drug-eluting stent trials and is Principal Investigator of four trials focusing on the safety and efficacy of renal sympathetic denervation in hypertension, heart failure, vasospastic angina and heart failure. Dr Daemen is a member of the editorial board of EuroIntervention and the Netherlands Heart Journal, member of Young ICIN, and has completed courses in biomedical statistics and device training.

View full profile
Dagmara Hering

Dagmara Hering

Professor

Prof Dagmara Hering is a medical scientist and clinical specialist in internal medicine, a specialist in hypertension, and a cardiologist at the Medical University of Gdansk, Gdansk, PL.


She is also a Professorial Fellow at Baker IDI Heart and Diabetes Institute, Melbourne, AU and a Clinical Expert of the European Society of Hypertension, and a Fellow of the European Society of Cardiology.


Her clinical research has been focused on the role of the sympathetic nervous system in hypertension, and cardiovascular and renal diseases, and has substantially contributed to the understanding of the efficacy of device-based therapies including renal denervation.

View full profile

Comments

You must be to comment. If you are not registered, you can register here.